Figure 1



Study Design
Screen/TNF and/or DMARD withdrawal period
Randomisation
Treatment period
Post-treatment period
Methotrexate (MTX) for ≥ 3 months
Rituximab + MTX (Group A) n=300
Placebo + MTX (Group B) n=200
Screen
Day 1
Day 15
Wk 4
Wk 8
Wk 12
Wk 16
Wk 20
Wk 24
Visits every 2 months
Month 24
Rescue therapy
Rituximab or placebo infusion
Clinic visit
Primary efficacy timepoint
Group B: Rituximab + MTX
Group A: Standard of care

Figure 2



ACR Responses at 6 months (ITT)
% patients
60
50
40
30
20
10
0
18
5
1
P < 0.0001
51
P < 0.0001
27
P < 0.0001
12
Placebo (n=201)
Rituximab 2x1000mg (n=298)
ACR20 ACR50 ACR70
P-values from CMH test, comparing the placebo group with each rituximab group
Patients with insufficient data to calculate an ACR response are classed as non-responders
27

Figure 3



ACR20 Responses (ITT)
% Patients with ACR20
60
50
40
30
20
10
0
0
4
8
12
16
20
24
Weeks
Placebo (n=201)
Rituximab 2x1000mg (n=298)
28

Figure 4



Change in DAS28 at 6 months (ITT)
Placebo
(n=201)
Rituximab 2x1000mg
(n=298)
0
-0.2
-0.4
-0.6
-0.8
-1
-1.2
-1.4
-1.6
-1.8
-2
Mean Change in DAS28
-0.34
Change of minimal clinical significance
-1.83
p < 0.0001
29

Figure 5




Figure 5

Figure 6



EULAR Remission, Low Disease at 6 months (ITT)
% patients
16
14
12
10
8
6
4
2
0
2
0
15
9
Placebo (n=201)
Rituximab 2x1000mg (n=298)
Low Disease
Remission
Low Disease = DAS ≤3.2
Remission = DAS <2.6
31

Figure 7



Median CRP (ITT)
Median CRP (mg/dL)
3
2.5
2
1.5
1
0.5
0
0
4
8
12
16
20
24
Weeks
Upper limit of normal
Placebo (n=201)
Rituximab 2x1000mg (n=298)
32

Figure 8



Proportion of Patients with clinically relevant improvement in function at 6 months (ITT)
% patients
60
50
40
30
20
10
0
50.7
19.9
Placebo (n=201)
Rituximab 2x1000mg (n=298)
Clinically relevant improvement defined as fall in HAQ score of ≥0.25
33

Figure 9



Percentage change in ACR Core set at 6 months (ITT)
SJC
TJC
Pt GH
Ph GH
HAQ
Pain
CRP
ESR
Adjusted mean % Change
100
80
60
40
20
0
-20
-40
-60
-4
-41
*
8
-40
*
-5
-28
**
-3
-38
*
-7
-27
*
2
-25
**
90
-27
*
12
-36
*
* P<0.0001, **p<0.01
34

Figure 10



Change in FACIT-F at 6 months (ITT)
Placebo
(n=201)
Rituximab 2x1000mg
(n=298)
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
Adjusted Mean Change in FACIT
-0.39
Change of minimal clinical significance
-8.97
p < 0.0001
35

Figure 11



Changes in SF-36 Categories
Mental Health
Physical Health
% patients
90
80
70
60
50
40
30
20
10
0
20.3
65
14.7
p=0.0015
37.8
49
13.3
12.7
60.2
7.1
p<0.0001
48
46.3
5.8
Placebo (n=201)
Rituximab 2x1000mg (n=298)
Placebo (n=201)
Rituximab 2x1000mg (n=298)
Improved
Unchanged
Worsened
36

Figure 12



Total Rheumatoid Factor (ITT)
Mean RF (IU/mL)
350
300
250
200
150
100
50
0
0
4
8
12
16
20
24
Weeks
Placebo (n=201)
Rituximab (n=298)
37

Figure 13



Mean Change in Sharp-Genant Total Score (ITT)
Mean Change in Sharp-Genant (Total Score)
1.5
1
0.5
0
0
4
8
12
16
20
24
Weeks
Placebo (n=177)
Rituximab 2x1000mg (n=268)
All observed radiographic data. No imputation for missing values
38

Figure 14



Mean Change in Sharp-Genant Erosion Score (ITT)
Mean Change in Sharp-Genant (Erosion Score)
1
0.8
0.6
0.4
0.2
0
0
4
8
12
16
20
24
Weeks
Placebo (n=177)
Rituximab 2x1000mg (n=268)
All observed radiographic data. No imputation for missing values
40

Figure 15



Mean Change in Sharp-Genant JSN Score (ITT)
Mean Change in Sharp-Genant (JSN Score)
0.5
0.4
0.3
0.2
0.1
0
0
4
8
12
16
20
24
Weeks
p = 0.0156
Placebo (n=177)
Rituximab 2x1000mg (n=268)
All observed radiographic data. No imputation for missing values
41

Figure 16



Proportion of Patients with no change in erosion score (ITT)
% patients
67
66
65
64
63
62
61
60
59
58
57
66
60
Placebo (n=177)
Rituximab 2x1000mg (n=268)
All observed radiographic data. No imputation for missing values
42

Figure 17




Change in Radiographic Endpoints at Week 24 (Exploratory Endpoint)
Total Genant-Modified Sharp Score
2
1.5
1
0.5
0
p=0.1693
1.2
0.6
p=0.0156*
0.5
0.2
p=0.2358
0.8
0.4
Genant-Modified Total Sharp Score
Total Joint Space Narrowing Score
Total Erosion Score
Placebo (N=177)
Rituximab (N=268)
*Statistically significant at the 0.05 level
24 Placebo and 30 rituximab patients were missing x-rays at week 24

Figure 18



Mean % Change in ACR Core Set Parameters at Week 24 (ITT)

	Placebo (N=201)	Rituximab (N=298)	p-value
Swollen Joint Count (%)	-3.6	-41.1	<0.0001
Tender Joint Count (%)	8.4	-39.9	<0.0001
Patient's Global Assessment (%)	-5.0	-28.4	0.0048
Physician's Global Assessment (%)	-3.2	-38.4	<0.0001
HAQ (%)	-6.9	-27.0	<0.0001
Pain (%)	1.7	-25.3	0.0045
CRP (mg/dL- %)	89.7	-27.1	<0.0001
ESR (mm/h - %)	11.7	-29.5	<0.0001

Percentages are ANCOVA-adjusted
P values are from ANCOVA

Figure 19



Median CD19
Median CD19 (cells/ul)
500
400
300
200
100
0
0
6
12
18
24
Weeks
Placebo (n=201)
Rituximab 2x1000mg (n=298)
LOCF for missing values
44

Figure 20




Most commonly reported Adverse Event (Safety Pop)
Placebo (n=209)
Rituximab 2 x 1000 mg (n=308)
All Events 183 (88%) 261 (85%)
Rheumatoid Arthritis 87 (42%) 65 (21%)
Headache 19 (9%) 26 (8%)
URTI 14 (7%) 24 (8%)
Nasopharyngitis 12 (6%) 23 (7%)
Diarrhoea 16 (8%) 18 (6%)
Fatigue 12 (6%) 21 (7%)
Hypertension 11 (5%) 21 (7%)
Arthralgia 10 (5%) 17 (6%)
Nausea 5 (2%) 22 (7%)
UTI 16 (8%) 10 (3%)
Number of patients (%)
45

Figure 21




Adverse Events Leading to Withdrawal

	Placebo (n=209)	Rituximab 2 x 1000 mg (n=308)
All Events	2 (<1%)	8 (3%)
Cough*	-	1 (<1%)
Hoarseness*	-	1 (<1%)
Laryngeal Oedema*	-	1 (<1%)
Urticaria*	-	2 (<1%)
Cardiac Tamponade	-	1 (<1%)
Anaphylactic Reaction*	-	1 (<1%)
Rheumatoid Arthritis	-	1 (<1%)
Gastric Cancer	1 (<1%)	-
Abortion (spontaneous)	-	1 (<1%)

Number of patients (%) *Associated with infusion

46

Figure 22



Events occurring during/within 24h of Infusions

	First Infusion		Second Infusion	
	Placebo (n=209)	Rituximab (n=308)	Placebo (n=209)	Rituximab (n=308)
All Events	49 (23%)	88 (29%)	29 (14%)	35 (11%)
Headache	10 (5%)	15 (5%)	2 (<1%)	3 (<1%)
Hypertension	4 (2%)	9 (3%)	4 (2%)	7 (2%)
Nausea	2 (<1%)	8 (3%)	-	2 (<1%)
Pruritus	2 (<1%)	7 (2%)	-	-
Urticaria	1 (<1%)	7 (2%)	-	-
Insomnia	2 (<1%)	6 (2%)	-	-
Flushing	2 (<1%)	5 (2%)	1 (<1%)	2 (<1%)
Pyrexia	1 (<1%)	5 (2%)	2 (<1%)	-
Throat Irritation	-	4 (1%)	-	1 (<1%)
Tachycardia	7 (3%)	3 (<1%)	-	2 (<1%)

Number of patients (%)

47

Figure 23



Acute Infusion Reactions
25
20
15
10
5
0
% patients
18
23
11
8
1st Infusion
2nd Infusion
Placebo (n=209)
Rituximab (n=308)
48

Figure 24



Serious Adverse Events Occurring during/within 24h of infusion
Placebo (n=209)
Rituximab 2 x 1000 mg (n=308)
First Infusion
All Events 1 (<1%) 1 (<1%)
Anaphylactic Reaction - 1 (<1%)
Diabetes Mellitus 1 (<1%) -
Second Infusion
All Events 2 (<1%) 1 (<1%)
Chest Pain 1 (<1%) -
Intestinal Abscess 1 (<1%) -
Hypertension - 1 (<1%)
Number of patients (%)
49

Figure 25




System Organ Class (Safety Pop.)
Infections & Infestations
Placebo (n=209)
Rituximab 2 x 1000 mg (n=308)
All Events 79 (38%) 127 (41%)
URTI 17 (7%) 24 (8%)
Nasopharyngitis 12 (6%) 23 (7%)
UTI 16 (8%) 10 (3%)
Bronchitis 12 (6%) 13 (4%)
Sinusitis 11 (5%) 10 (3%)
Rhinitis 4 (2%) 8 (3%)
Herpes simplex 6 (3%) 4 (1%)
Influenza 3 (1%) 4 (1%)
Gastroenteritis 2 (<1%) 4 (1%)
Cystitis 1 (<1%) 4 (1%)
Number of patients (%)
50

Figure 26



Serious Infections

	Placebo (n=209)	Rituximab 2 x 1000 mg (n=308)
All Serious Infections	2 (<1%)	6 (2%)
Intestinal Abscess	1 (<1%)	-
Gangrenous Cellulitis	-	1 (<1%)
Central line infection	1 (<1%)	-
Gastroenteritis	-	1 (<1%)
Hepatitis B (de novo)	-	1 (<1%)
Infection	-	1 (<1%)
Influenza	-	1 (<1%)
Pyelonephritis	-	1 (<1%)
Zoonosis	-	1 (<1%)

Number of patients (%)

51

Figure 27



Infection Rate
Placebo (n=209)
Rituximab 2 x 1000 mg (n=308)
Events per 100 Patient years
All Infections
155
138
Clinically significant Infections*
3.65
5.2
*Serious and/or those requiring i.v. antibiotics
52

Figure 28



HACA (ITT)
Placebo (n=201)
Rituximab 2 x 1000 mg (n=298)
Positive at week 24
0/197 (0%)
12/287 (4%)
53

Figure 29



IgG (Safety population)
IgG (mg/mL)
15
10
5
0
Lower Limit of Normal
Weeks
0
4
8
12
16
20
24
Placebo
Rituximab
LLN
54

Figure 30




IgA (Safety population)
IgA (mg/mL)
4
3
2
1
0
Lower Limit of Normal
Weeks
0
4
8
12
16
20
24
Placebo
Rituximab
LLN
65

Figure 31


IgM (Safety population)
IgM (mg/mL)
2
1.5
1
0.5
0
Lower Limit of Normal
Weeks
0
4
8
12
16
20
24
Placebo
Rituximab
LLN
56



FR1
CDR1
10
20
30
40
2H7
QIVLSQSPAILSASPGEKVTMTC [RASSSVS-YMH] WYQQKP
hu2H7.v16
DIQMTQSPSSLSASVGDRVTITC [RASSSVS-YMH] WYQQKP
hum KI
DIQMTQSPSSLSASVGDRVTITC [RASQSISNYLA] WYQQKP
FR2
CDR2
FR3
50
60
70
80
2H7
GSSPKPWIY [APSNLAS] GVPARFSGSGSGTSYSLTISRVEA
hu2H7.v16
GKAPKPLIY [APSNLAS] GVPSRFSGSGSGTDFTLTISSLQP
hum KI
GKAPKLLIY [AASSLES] GVPSRFSGSGSGTDFTLTISSLQP
CDR3
FR4
90
100
2H7
EDAATYYC [QQWSFNPPT] FGAGTKLELKR
hu2H7.v16
EDFATYYC [QQWSFNPPT] FGQGTKVEIKR
hum KI
EDFATYYC [QQYNSLPWT] FGQGTKVEIKR

Figure 32A



FR1
CDR1
10
20
30
40
2H7
QAYLQQSGAELVRPGASVKMSCKAS [GYTFTSYNMH] WVKQT
hu2H7.v16
EVQLVESGGGLVQPGGSLRLSCAAS [GYTFTSYNMH] WVRQA
hum III
EVQLVESGGGLVQPGGSLRLSCAAS [GFTFSSYAMS] WVRQA
FR2
CDR2
FR3
50 a
60
70
80
2H7
PRQGLEWIG [AIYPGNGDTSYNQKFKG] KATLTVDKSSSTAYM
hu2H7.v16
PGKGLEWVG [AIYPGNGDTSYNQKFKG] RFTISVDKSKNTLYL
hum III
PGKGLEWVA [VISGDGGSTYYADSVKG] RFTISRDNSKNTLTL
CDR3
FR4
abc
90
100abcde
110
2H7
QLSSLTSEDSAVYFCAR [VVYYSNSYWYFDV] WGTGTTVTVSS
hu2H7.v16
QMNSLRAEDTAVYYCAR [VVYYSNSYWYFDV] WGQGTLVTVSS
hum III
QMNSLRAEDTAVYYCAR [GRVGYSLY---DY] WGQGTLVTVSS

Figure 32B

Figure 33

DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKS
GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK
VYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:13)

Figure 34

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQK
FKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK (SEQ ID NO:14)

Figure 35

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQK
FKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNATYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIAATISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
TQKSLSLSPGK (SEQ ID NO:15)

```
                    10        20        30        40        50
hu2H7.v16.light     DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAP
                    **********************.*******************
hu2H7.v138.light    DIQMTQSPSSLSASVGDRVTITCRASSSVSYLHWYQQKPGKAPKPLIYAP
                    10        20        30        40        50

                    60        70        80        90        100
hu2H7.v16.light     SNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQG
                    ************************************.*********
hu2H7.v138.light    SNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWAFNPPTFGQG
                    60        70        80        90        100

                    110       120       130       140       150
hu2H7.v16.light     TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD
                    **************************************************
hu2H7.v138.light    TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD
                    110       120       130       140       150

                    160       170       180       190       200
hu2H7.v16.light     NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL
                    **************************************************
hu2H7.v138.light    NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL
                    160       170       180       190       200

                    210
hu2H7.v16.light     SSPVTKSFNRGEC
                    *************
hu2H7.v138.light    SSPVTKSFNRGEC
                    210
```

Figure 36



hu2H7.v16.heavy
hu2H7.v138.heavy
EVQLVESGGGLVQPGGSLRLSCAAASGYTFTSYNMHWVRQAPGKGLEWVGA
IYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVV
YYSNSYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT
QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Figure 37

```
                1
hu2H7.v16       DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAP
                                                32
                ********************************.*******************
hu2H7.v511      DIQMTQSPSSLSASVGDRVTITCRASSSVSYLHWYQQKPGKAPKPLIYAP
                52
hu2H7.v16       SNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQG
                ****************************************.*********
hu2H7.v511      SNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWAFNPPTFGQG
                102
hu2H7.v16       TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD
                ****************************************************
hu2H7.v511      TKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD
                152
hu2H7.v16       NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL
                ****************************************************
hu2H7.v511      NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGL
                202             214
hu2H7.v16       SSPVTKSFNRGEC
                *************
hu2H7.v511      SSPVTKSFNRGEC
```

Figure 38

Figure 39

```
                  1
hu2H7.v16         EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHW
                  ************************************
hu2H7.v511        EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHW

                 37              52a                                82abc
hu2H7.v16         VRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSL
                  ********************* ****************************
hu2H7.v511        VRQAPGKGLEWVGAIYPGNGATSYNQKFKGRFTISVDKSKNTLYLQMNSL

                 83                 100abcde           113
hu2H7.v16         RAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
                  ******************  ******************
hu2H7.v511        RAEDTAVYYCARVVYYSYRYWYFDVWGQGTLVTVSS

                118
hu2H7.v16         ASTKGPSVFPLAPS
                  **************
hu2H7.v511        ASTKGPSVFPLAPS

                132
hu2H7.v16         SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
                  **************************************************
hu2H7.v511        SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS

                182
hu2H7.v16         LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
                  **************************************************
hu2H7.v511        LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA

                232
hu2H7.v16         PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG
                  **************************************************
hu2H7.v511        PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG

                282
hu2H7.v16         VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP
                  ***************.**************************** *****
hu2H7.v511        VEVHNAKTKPREEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNAALPAP

                332
hu2H7.v16         IEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW
                  *  **********************************************
hu2H7.v511        IAATISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW

                382
hu2H7.v16         ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
                  **************************************************
hu2H7.v511        ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA

                432             447
hu2H7.v16         LHNHYTQKSLSLSPGK
                  ****************
hu2H7.v511        LHNHYTQKSLSLSPGK
```

Figure 40

Fig. 40A **Humanized 2H7.v114 Variable Light-Chain Domain:**

DIQMTQSPSSLSASVGDRVTITCRASSSVSYLHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSG

TDFTLTISSLQPEDFATYYCQQWAFNPPTFGQGTKVEIKR

Fig. 40B **Humanized 2H7.v114 Variable Heavy-Chain Domain:**

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGATSYNQK

FKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSASYWYFDVWGQGTLVTVSS

Fig. 40C **Humanized 2H7.v114 Full-Length Heavy Chain:**

EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNG

ATSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSASYWYFDVWGQG

TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA

VLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP


APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP

REEQYNATYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIAATISKAKGQPREPQVYTL

PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT

VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

Patient disposition




*numbers represent patients with radiographic data available at 56 weeks

[redacted]

Figure 41

Change in radiographic endpoints at week 56




Primary analysis: radiographs within time window, linear extrapolation from Week 24 for missing values

[redacted]

Figure 42

Mean change in total Sharp-Genant score over time




Observed analysis including patients with radiographs at baseline, Week 24 and Week 56

[redacted]

Figure 43

Cumulative distribution of change in total Sharp-Genant score



[redacted]

Figure 44


Sensitivity analyses: change in total Sharp-Genant score

	[redacted]	[redacted]	[redacted]
Median imputation for missing values	1.63 (n=184)	0.62 (n=273)	<0.0001
All radiographs, linear extrapolation for missing values	2.17 (n=186)	0.92 (n=277)	0.0094
All radiographs, completer analysis	2.17 (n=156)	0.88 (n=242)	0.0090

[redacted]

Figure 45

Patients with no radiographic changes at Week 56



Primary analysis: radiographs within time window, linear extrapolation from Week 24 for missing values

[redacted]

Figure 46